A comparison of the prognosis of papillary and clear cell renal cell carcinoma

Deng, Jun; Li, Lei; Xia, Haimei; Guo, Ju; Wu, Xin; Yang, Xiaorong; Hong, Yan‐Yan; Chen, Qingke; Hu, Jielun

doi:10.1097/md.0000000000016309

Cited by 45 publications

(33 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6][7][8] However, conflicting results were observed in other studies, in which metastatic pRCC and metastatic ccRCC had similar prognoses. 9,10 In addition to the current contradictory evidence, few studies have focused on comprehensive subgroup analyses based on demographic and clinical factors. In the present study, our purpose was to evaluate the survival outcomes of pRCC and ccRCC using the Surveillance, Epidemiology, and End Results (SEER) database.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma

Huang

Yan

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…For example, some studies concluded that the prognosis of localized pRCC was more favorable than that of ccRCC, while the prognosis of advanced/metastatic pRCC was worse than that of ccRCC 6‐8 . However, conflicting results were observed in other studies, in which metastatic pRCC and metastatic ccRCC had similar prognoses 9,10 …”

Section: Introductionmentioning

confidence: 99%

Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma

Huang

Yan

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Exophytic renal tumors tended to be associated with lower pathologic grade and the presence of papillary renal cell carcinoma subtype when compared with endophytic renal tumors [ 25 ]. Papillary renal cell carcinoma is reported to have better outcomes than clear cell renal cell carcinoma in patients without metastases [ 26 ]. Furthermore, the presence of an angular interface with the normal renal parenchyma is strongly related to benignity in an exophytic renal mass.…”

Section: Discussionmentioning

confidence: 99%

Single-Site Sutureless Partial Nephrectomy for Small Exophytic Renal Tumors

Chien

Huang

et al. 2020

JCM

View full text Add to dashboard Cite

Partial nephrectomy (PN) is the standard procedure for most patients with localized renal cancer. Laparoscopy has become the preferred surgical approach to target this cancer, but the steep learning curve with laparoscopic PN (LPN) remains a concern. In LPN intracorporeal suturing, the operation time is further extended even under robot assistance, a step which prolongs warm ischemic time. Herein, we shared our experience to reduce the warm ischemia time, which allows surgeons to perform LPN more easily by using a combination of hemostatic agents to safely control parenchymal bleeding. Between 2015 and 2018, we enrolled 52 patients who underwent LPN in our hospital. Single-site sutureless LPN and traditional suture methods were performed in 33 and 19 patients, respectively. Preoperative, intra-operative, and postoperative variables were recorded. Renal function was evaluated by estimated glomerular filtration rate (eGFR) pre- and postoperatively. The average warm ischemia time (sutureless vs. suture group; 11.8 ± 3.9 vs. 21.2 ± 7.2 min, p < 0.001) and the operation time (167.9 ± 37.5 vs. 193.7 ± 42.5 min, p = 0.035) were significantly shorter in the sutureless group. In the sutureless group, only 2 patients suffered from massive urinary leakage (>200 mL/day) from the Jackson Pratt drainage tube, but the leakage spontaneously decreased within 7 days after surgery. eGFR and serum hemoglobin were not found to be significantly different pre- and postoperatively. All tumors were removed without a positive surgical margin. All patients were alive without recurrent tumors at mean postoperative follow-ups of 29.3 ± 12.2 months. Single-site sutureless LPN is a feasible surgical method for most patients with small exophytic renal cancer with excellent cosmetic results without affecting oncological results.

show abstract

“…The incidence of RCC has been increasing in the recent decades, which accounts for 3% of all adult malignancies and ranks the 13th most common malignancy diagnosed worldwide annually. RCC originates from renal epithelial cells (1), and nearly 70-80% cases of RCC is ccRCC pathologic subtype (2). Late diagnosis is a major obstacle to improving ccRCC outcomes, with the fact of about 33% of ccRCC patients initially diagnosed as advanced stage and 40% of those will eventually have distant metastasis.…”

Section: Introductionmentioning

confidence: 99%

The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis Prediction of Clear Cell Renal Cell Carcinoma

Mou

Zhang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Clear cell renal cell carcinoma (ccRCC) is characteristics of resistance to chemotherapy and radiotherapy. The prognosis of ccRCC was dismay with immense diversity. Iron metabolism disturbance is a common phenomenon in ccRCC. The purpose of our study is to identify and validate the candidate prognostic gene signature of iron metabolism and methylation closely related to the poor prognosis of ccRCC through comprehensive bioinformatics analysis in The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Methods: The prognostic iron metabolism-related genes were screened according to the overlapping differentially expressed genes (DEGs) from the TCGA database. We built a prognostic model using risk score method to predict OS, each ccRCC patient's risk score was calculated, and the resulting score can divide these patients into two categories according to the cut-point risk score. The prognostic significance of the hub genes was further evaluated with the Kaplan-Meier (KM) survival and Receiver Operating Characteristic (ROC) curve analysis. Univariate and multivariate Cox regression analysis was implemented to evaluate the impact of each variable on OS. Furthermore, the prediction power of the 25 gene signatures has been validated using an independent ccRCC cohort from the GEO database. The Gene Set Enrichment Analysis (GSEA) identified the characteristics of hub related oncogenes. Finally, we utilize Weighted Gene Co-expression Network Analysis (WGCNA) to investigate the co-expression network based on these DEGs. Results: In this study, we identified and validated 25 iron metabolism-related and methylated genes as the prognostic signatures, which differentiated ccRCC patients into high and low risk subgroups. The KM analysis showed that the survival rate of the high-risk patients was significantly lower than that of the low-risk patients. The risk score calculated with 25 gene signatures could largely predict OS and DFS for 1, 3, and 5 years in patients with ccRCC. Mou et al. Iron Metabolism Gene Predicts Prognosis in ccRCC Conclusions: Taken together, we identified the key iron metabolism-related and methylated genes for ccRCC through a comprehensive bioinformatics analysis. This study provides a reliable and robust gene signature for the prognostic predictor of ccRCC patients and maybe provides a promising treatment strategy for this lethal disease.

show abstract

A comparison of the prognosis of papillary and clear cell renal cell carcinoma

Abstract: Supplemental Digital Content is available in the text

Cited by 45 publications

References 43 publications

Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma

Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma

Single-Site Sutureless Partial Nephrectomy for Small Exophytic Renal Tumors

The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis Prediction of Clear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About